 | Info
Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
 | Out-
side |
| | | | |
|
| | | | |
Result : Searchterm 'Magnevist' found in 2 terms [ ] and 6 definitions [ ]
| | 1 - 5 (of 8) nextResult Pages : [1] [2] |  | |  | Searchterm 'Magnevist' was also found in the following service: | | | | |
| |  |
| |
|
Magnevist® is a paramagnetic ionic contrast agent for use in magnetic resonance imaging. Contrast enhanced MRI with Magnevist® allows additional diagnostic information of tumors, inflammation and vascular lesions and the determination or differentiation of such lesions.
The contrast enhancing effect is produced by the di-N-methylglucamine salt of gadopentetate (Gd-DTPA), the gadolinium complex of diethylenetriamine pentaacetic acid. Magnevist® has the strongest effect on T1 weighted images, by increasing T1 signal intensity in tissues where Magnevist® has accumulated.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Ionic Intravenous Contrast Agents and Gadopentetate Dimeglumine.
|
|
Drug Information and Specification |
| NAME OF COMPOUND |
Gadopentetate dimeglumine, Gd-DTPA |
| DEVELOPER |
Bayer Schering Pharma AG, Germany |
| CENTRAL MOIETY |
Gd3+ |
| CONTRAST EFFECT |
T1, Predominantly positive enhancement |
| RELAXIVITY |
r1=3.4, r2=3.8, B0=1.0T |
| PHARMACOKINETIC |
Intravascular, extracellular, renal excretion |
| OSMOLALITY |
1960 mosm/kgH2O |
| CONCENTRATION |
0.5 mol/L |
| DOSAGE |
0.1-0.3 mmol/kg / 0.2-0.6 mL/kg |
| PREPARATION |
Finished product |
| INDICATION |
Neuro/whole body |
| DEVELOPMENT STAGE |
For sale |
| DISTRIBUTOR |
See below |
| PRESENTATION |
Vials of 5, 10, 15, 20 and 100 mL bulk package
Pre-filled syringes of 10, 15 and 20 mL |
| DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING
PACKAGE INSERT |
|
|
| | | | | | • Share the entry 'Magnevist®':    | | | | |  Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | | | |
| |
|
| | | |
• View the DATABASE results for 'Magnevist® Enteral' (3).
| | | | |
| | | | |  |
| |
|
The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.
|
| |
|
| | | |
• View the DATABASE results for 'Bayer Schering Pharma AG' (22).
| | |
• View the NEWS results for 'Bayer Schering Pharma AG' (25).
| | | | | | Further Reading: | News & More:
|
|
| |
| | | Searchterm 'Magnevist' was also found in the following service: | | | | |
| | |
| |
|
| | | |
• View the DATABASE results for 'Extracellular Fluid Agents' (2).
| | | | |
| | | | | |
| |
|
Short name: Gd-DTPA, generic name: Gadopentetate dimeglumine, chemical compound: Gadolinium-diethylenetriaminepentaacetic acid
Gadopentetate dimeglumine was introduced in 1981, as the first paramagnetic MRI contrast agent (ionic). The Gd-induced dipole dipole interactions lead to shortening of T1, which results in contrast enhancement on T1 weighted images. The used metal ion Gd3+ (gadolinium) is toxic, and therefore bound in the renally excreted DTPA chelate, a very stable complex. The Gd-complex also induce susceptibility effects, as a result of the magnetic field gradient between the contrast agent in the blood vessels and the surrounding tissue, that lead to shortening of T2 or T2*.
Following intravenous administration, the compound is distributed rapidly in the extracellular space and is eliminated unchanged by glomerular filtration via the kidneys. Up to 6 hours, post injection an average of 83% of the dose is eliminated renal.
See also Magnevist®, Gadolinium and Contrast Agents.
|
| | | |
• View the DATABASE results for 'Gadopentetate Dimeglumine' (5).
| | | | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | |
| | | 1 - 5 (of 8) nextResult Pages : [1] [2] |
| |
|
| |
 | Look
Ups |
| |
Random Page
top
